Journal of Clinical Oncology

Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial

E Edward R. Scheffer Cliff (1Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia) T Thomas E. Lew (The Royal Melbourne Hospital and Peter MacCallum Cancer Centre;Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia) F Florian Simon (Department I of Internal Medicine, Center of Integrated Oncology Aachen Bonn Cologne Düsseldorf, University Hospital of Cologne, Cologne, Germany) T Talal Hilal (13Mayo Clinic, Phoenix, AZ) M Mary Ann Anderson (Peter MacCallum Cancer Centre, Melbourne, VIC, Australia) P Philip A. Thompson (24Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia) J John F. Seymour (Department of Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia)
View Original
APA MLA Chicago BibTeX RIS

Article Details

Volume / Issue Vol. 44, Issue 3
Published January 20, 2026
Pages 254-256
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins
ISSN: 0732-183X Health Sciences

Authors (7)

E

Edward R. Scheffer Cliff

1Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia

T

Thomas E. Lew

The Royal Melbourne Hospital and Peter MacCallum Cancer Centre;Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia

F

Florian Simon

Department I of Internal Medicine, Center of Integrated Oncology Aachen Bonn Cologne Düsseldorf, University Hospital of Cologne, Cologne, Germany

T

Talal Hilal

13Mayo Clinic, Phoenix, AZ

M

Mary Ann Anderson

Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

P

Philip A. Thompson

24Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia

J

John F. Seymour

Department of Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

Related Articles from this Journal

Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer

Ismaela Anna Vascotto, Filippo Antonica et al. Aug 2026 10.1200/jco-26-00658

Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial

Samer A. Srour, Jad Chahoud et al. Aug 2026 10.1200/jco-26-00388

Adjuvant Carboplatin for Early-Stage, Triple-Negative Breast Cancer: Taxane and Patient Selection

Risako Komata, Kenju Ando et al. Aug 2026 10.1200/jco-26-00140

Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE)

Ghayas C. Issa, Branko Cuglievan et al. Aug 2026 10.1200/jco-26-01743

Reply to: Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer

Irbaz Bin Riaz, R. Bryan Rumble et al. Aug 2026 10.1200/jco-26-01001